Trials / Completed
CompletedNCT03238443
Interest of the Donor-specific Antibodies After Liver Transplantation
Interest of the Donor-specific and Complement-binding Anti-HLA Antibodies (C1q) Assays for the Management and the Monitoring After Liver Transplant
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a prospective observational mono center study Primary objective : Study the anti-HLA antibodies frequency preformed before liver transplantation and the kinetic of appearance of DSA and de novo complement-binding anti-HLA antibodies after liver transplantation. Secondary objective : * Risk factor of de novo DSA appearance (Immunosuppressive therapy, liver aetiology) * Impact of DSA on: * Graft and patients survivals * Onset of allograft rejection (acute, late-onset, chronic) * Unexplained liver graft dysfunction * Unexplained liver enzymes abnormalities * Liver fibrosis development (liver stiffness study using fibroscan©)
Conditions
Timeline
- Start date
- 2016-02-16
- Primary completion
- 2019-07-13
- Completion
- 2019-07-13
- First posted
- 2017-08-03
- Last updated
- 2021-03-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03238443. Inclusion in this directory is not an endorsement.